t
Novacyt S.A. announced that its Chairman and PDMR, James Wakefield, purchased 7,000 ordinary shares in the company on 07 July 2022. The shares were acquired at £1.17 each on AIM. This transaction increased his beneficial holding to 43,839 ordinary shares, representing 0.06% of the company's issued share capital.
| Date | 7 Jul 2022 |
| Time | 15:00:06 |
| Category | Director/PDMR dealings |
| ID | 7299R |
Novacyt S.A.
("Novacyt" or the "Company")
Director/PDMR Shareholding
Paris, France and Camberley, UK - 07 July 2022 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 07 July 2022, the following Director purchased ordinary shares of €1/15 each in the Company (the "Ordinary Shares"):
|
Director |
Title |
Number of Ordinary Shares purchased |
Price paid per Ordinary Share |
Resultant beneficial holding |
% of issued share capital |
|
James Wakefield |
Chairman |
7,000
|
£1.17 |
43,839 |
0.06%
|
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
James Wakefield Chairman
|
||||
|
2. |
Reason for the Notification |
|||||
|
a) |
Position/status |
See 1(a) - classified as a PDMR of the Company
|
||||
|
b) |
Initial notification/ Amendment |
Initial Notification
|
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
Novacyt S.A. |
||||
|
b) |
LEI |
213800BWAC2BF295EG28 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the Financial instrument, type of instrument |
ordinary shares of €1/15 each
|
||||
|
|
Identification code |
FR0010397232 |
||||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information: · Aggregated volume · Price |
|
||||
|
e) |
Date of the transaction |
7 July 2022 |
||||
|
f) |
Place of the transaction |
AIM |
||||
- End -
Contacts
Novacyt SA
David Allmond, Chief Executive Officer
James McCarthy, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Numis Securities Limited (Joint Broker)
James Black / Freddie Barnfield / Duncan Monteith
+44 (0)20 7260 1000
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick Petit
+33 (1) 42 22 10 10
[email protected]; [email protected]
FTI Consulting (International)
Victoria Foster Mitchell / Alex Shaw
+44 (0)20 3727 1000
[email protected] / [email protected]
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 48
About Novacyt Group
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company supplies an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.
For more information, please refer to the website: www.novacyt.com